Date: 2014-10-28
Type of information: Presentation of results at a congress
phase:
Announcement: presentation of results at the World ADC Summit, San Diego, CA
Company: Innate Pharma (France)
Product: antibody drug conjugate (ADC) technology
Action
mechanism: Innate Pharma’s coupling technology uses bacterial transglutaminase (BTG) enzyme. It aims to address the heterogeneity of the coupling between the antibody and the drug of interest, heterogeneity that affects the therapeutic efficacy of antibody conjugates. With this technology, a single point mutation in the antibody’s heavy chain generates either two or four enzyme-recognition sites, and linkers have been optimized to couple quantitatively at these positions. The process results in homogeneous ADCs with a drug-to-antibody ratio of exactly 2:1 or 4:1 in a robust and time-efficient manner. The coupling is site-specific with minimal antibody scaffold modification, therefore only adding two steps in an already well-established manufacturing procedure widely accepted by regulators.
Disease:
Therapeutic area: Technology - Services
Country:
Trial details:
Latest
news: * On October 28, 2014, Innate Pharma, the innate immunity company developing first-in-class therapeutic antibodies for cancer and inflammatory diseases, announced that two posters showing new sets of preclinical data on its new, site-specific conjugation technology (“BTG-ADC”) have been presented at the World ADC Summit, San Diego, CA. The key conclusion of these posters is that ADCs generated by BTG-ADC show an improved therapeutic index in in vivo models compared to Adcetris®, one of the two reference ADCs approved by FDA, with a significantly higher maximum tolerated dose (>60mg/kg vs 18 mg/kg) and a higher specific tumoral uptake. Furthermore, Innate Pharma’s BTG-ADC technology is a rapid and versatile process appropriate for generating and testing various linkers and toxins such as PBDs , in high-throughput screening. A presentation of this technology will be held at the upcoming European Antibody congress 2014, in Geneva, November 11, 2014 by Prof. Schibli, ETH-Hönggerberg, scientific collaborator of Innate Pharma, and will be available on Innate Pharma’s website. The first poster (“Site-specific conjugation by BTG improves the therapeutic index of ADC in vivo”) describes the in vitro and in vivo characterization of ADCs obtained using a Innate Pharma\'s site-specific conjugation technology based on Bacterial Transglutaminase (BTG). The second poster (“Versatility of Site-Specific Conjugation based on Bacterial Transglutaminase”) demonstrates the versatility and the potential of BTG site-specific conjugation for high-throughput screen ing of ADCs.
